ConductScience.org, home

Paper15959528

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.

Yanada M and 4 others. Leukemia, 2005. Cited by 227 papers, by iCite.

Cite this record

ConductScience Library. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Papers, record 15959528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15959528

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
PubMed
Journal
Leukemia
PubMed
Year
2005
PubMed
Publication types
Journal Article, Meta-Analysis
PubMed
Citations, by iCite
227
iCite
Relative citation ratio, by iCite
4.4
iCite
Revised in PubMed
2026-10-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yanada MM
2Matsuo KK
3Suzuki TT
4Kiyoi HH
5Naoe TT

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, MyeloidMajor topic
MutationMajor topic
Protein-Tyrosine KinasesMajor topic
Proto-Oncogene ProteinsMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Tandem Repeat SequencesMajor topic
Acute Disease
Disease-Free Survival
Humans
Prognosis
Proportional Hazards Models
Survival Rate
fms-Like Tyrosine Kinase 3

Source PubMed

Download CSV of topics

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13802833Meta-analysis in clinical trials.Control Clin Trials1986https://conductscience.org/library/papers/3802833PubMed
210502596Acute myeloid leukemia.N Engl J Med1999https://conductscience.org/library/papers/10502596PubMed
314726504CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.J Clin Oncol2004https://conductscience.org/library/papers/14726504PubMed
415167911FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.Hematol J2004https://conductscience.org/library/papers/15167911PubMed
515059064Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.Eur J Haematol2004https://conductscience.org/library/papers/15059064PubMed
611535508
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Blood2001https://conductscience.org/library/papers/11535508PubMed
711290608Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.Blood2001https://conductscience.org/library/papers/11290608PubMed
812200684Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.Leukemia2002https://conductscience.org/library/papers/12200684PubMed
910764154Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene.Leukemia2000https://conductscience.org/library/papers/10764154PubMed
1015054042Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.Blood2004https://conductscience.org/library/papers/15054042PubMed
119746770The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.Blood1998https://conductscience.org/library/papers/9746770PubMed
1215326195Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.J Clin Oncol2004https://conductscience.org/library/papers/15326195PubMed
1312899708Flt3 mutations and leukaemia.Br J Haematol2003https://conductscience.org/library/papers/12899708PubMed
1412522450Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).Hematol J2002https://conductscience.org/library/papers/12522450PubMed
157786990Operating characteristics of a rank correlation test for publication bias.Biometrics1994https://conductscience.org/library/papers/7786990PubMed
169751631Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.Cancer Res1998https://conductscience.org/library/papers/9751631PubMed
1712692518Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.Hematol J2003https://conductscience.org/library/papers/12692518PubMed
1810216104Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.Blood1999https://conductscience.org/library/papers/10216104PubMed
1912692519Prognostic significance of FLT3 ITD and D835 mutations in AML patients.Hematol J2003https://conductscience.org/library/papers/12692519PubMed
2011091200FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.Br J Haematol2000https://conductscience.org/library/papers/11091200PubMed

See all 40 referencesDownload CSV of references

Cited by118

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 227 citations.

PMIDTitleJournalYearIn PapersSource
42739525Indications for Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: State of the Art.J Clin Med2026https://conductscience.org/library/papers/42739525PubMed
42230462Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.Blood Res2026https://conductscience.org/library/papers/42230462PubMed
41940985Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.Ann Hematol2026https://conductscience.org/library/papers/41940985PubMed
41899095Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.J Clin Med2026https://conductscience.org/library/papers/41899095PubMed
41857060Overcoming vascular niche-mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition.NPJ Syst Biol Appl2026https://conductscience.org/library/papers/41857060PubMed
41537333All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the CON.Haematologica2026https://conductscience.org/library/papers/41537333PubMed
41082569Structure-guided discovery and characterization of novel FLT3 inhibitors for acute myeloid leukemia treatment.PLoS One2025https://conductscience.org/library/papers/41082569PubMed
40181449Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib: a case report.J Med Case Rep2025https://conductscience.org/library/papers/40181449PubMed
39945223Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.Cancer2025https://conductscience.org/library/papers/39945223PubMed
39884265Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic Leukemia.Acta Haematol2025https://conductscience.org/library/papers/39884265PubMed
39601608New Approvals Advancing Blood Cancer Medicine.Blood Cancer Discov2025https://conductscience.org/library/papers/39601608PubMed
39237634Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.Leukemia2024https://conductscience.org/library/papers/39237634PubMed
39200232Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.Biomedicines2024https://conductscience.org/library/papers/39200232PubMed
38915455Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia.Mol Biol Res Commun2024https://conductscience.org/library/papers/38915455PubMed
38663769Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada.Transplant Cell Ther2024https://conductscience.org/library/papers/38663769PubMed
38007585TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.Leukemia2024https://conductscience.org/library/papers/38007585PubMed
37975931Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.Ann Hematol2024https://conductscience.org/library/papers/37975931PubMed
37847742A Year of Advances in Precision Therapy for Blood Cancers.Blood Cancer Discov2023https://conductscience.org/library/papers/37847742PubMed
37578642French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.Oncol Ther2023https://conductscience.org/library/papers/37578642PubMed
37457126How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Cancer Drug Resist2023https://conductscience.org/library/papers/37457126PubMed

See all 118 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15959528

GET https://conductscience.org/api/papers/v1/15959528/references?page=2